share_log

Morgan Stanley Upgrades C4 Therapeutics to Equal-Weight, Lowers Price Target to $1

Morgan Stanley Upgrades C4 Therapeutics to Equal-Weight, Lowers Price Target to $1

摩根士丹利将C4 Therapeutics上调至同等权重,将目标股价下调至1美元
Benzinga ·  2023/11/06 07:51

Morgan Stanley analyst Terence Flynn upgrades C4 Therapeutics (NASDAQ:CCCC) from Underweight to Equal-Weight and lowers the price target from $3 to $1.

摩根士丹利分析师特伦斯·弗林将C4 Therapeutics(纳斯达克股票代码:CCCC)从减持上调至同等权重,并将目标股价从3美元下调至1美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发